# Episode 139: Follicular Lymphoma Series, Pt 4 - Relapsed/Refractory Management (Cellular therapy options)

Page: https://stenobird.com/podcast/the-fellow-on-call-the-heme-onc-podcast-4669989/episode-139-follicular-lymphoma-series-pt-4-relapsed-refractory-management-cellular-therapy-options
Text version: https://stenobird.com/podcast/the-fellow-on-call-the-heme-onc-podcast-4669989/episode-139-follicular-lymphoma-series-pt-4-relapsed-refractory-management-cellular-therapy-options.md
Podcast: [The Fellow on Call: The Heme/Onc Podcast](https://stenobird.com/podcast/the-fellow-on-call-the-heme-onc-podcast-4669989)
Published: 2025-09-17T08:00:00+00:00
Episode link: https://www.thefellowoncall.com/tfocpodcast/follicularrelapsedrefractory2
Audio file: https://static1.squarespace.com/static/61b273ac9be6aa2250498c9e/t/68c9c5e476998a58a4088357/1758053883332/The+Fellow+On+Call+-+Follicular+Lymphoma+RR+Cellular+Therapy+-+Mix_FINAL.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/the-fellow-on-call-the-heme-onc-podcast-4669989/episodes/episode-139-follicular-lymphoma-series-pt-4-relapsed-refractory-management-cellular-therapy-options

## Resource

This week, we continue talking about relapsed/refractory follicular lymphoma, this time focusing on cellular therapy options, namely bispecific agents and CAR T therapy. If you have not done so, we highly recommend listening to part 3 of our follicular lymphoma series. You may also recall that we discussed these agents in our DLBCL series. Be sure to review our show notes from those episode for some awesome graphics and chart. Episode contents: - What are "CAR T" and "bispecific antibodies"? - What are the approved agents? - Selection of one therapy over another - Side effect profiles ** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes Love what you hear? Tell a friend and leave a review on our podcast streaming platforms! Twitter: @TheFellowOnCall Instagram: @TheFellowOnCall Listen in on: Apple Podcast, Spotify, and Google Podcast

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/the-fellow-on-call-the-heme-onc-podcast-4669989/episodes/episode-139-follicular-lymphoma-series-pt-4-relapsed-refractory-management-cellular-therapy-options/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/the-fellow-on-call-the-heme-onc-podcast-4669989/episode-139-follicular-lymphoma-series-pt-4-relapsed-refractory-management-cellular-therapy-options.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.